Blocking the BCR signaling pathway with inhibitors of the downstream kinases Bruton tyrosine kinase (BTK) or phosphoinositide-3-kinase (PI3K) effectively impairs cell survival and proliferation and has been proven to be a game-changing strategy for the management of CLL [4]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.